Background/Aims: Blocking estrogen signaling with endocrine therapies (Tamoxifen or Fulverstrant) is an effective treatment for Estrogen Receptor-α positive (ER + ) breast cancer tumours. Unfortunately, development of endocrine therapy resistance (ETR) is a frequent event resulting in disease relapse and decreased overall patient survival. The long noncoding RNA, H19, was previously shown to play a significant role in estrogen-induced proliferation of both normal and malignant ER + breast epithelial cells. We hypothesized that H19 expression is also important for the proliferation and survival of ETR cells. Methods: Here we utilized established ETR cell models; the Tamoxifen (Tam)-resistant LCC2 and the Fulvestrant and Tam cross-resistant LCC9 cells. Gain and loss of H19 function were achieved through lentiviral transduction as well as pharmacological inhibitors of the Notch and c-Met receptor signaling pathways. The effects of altered H19 expression on cell viability and ETR were assessed using three-dimensional (3D) organoid cultures and 2D co-cultures with low
Introduction
Estrogen signaling plays a central role in regulating the proliferation and survival of estrogen-dependent tumours that make up the majority of breast cancer cases [1] . Estrogen signaling is conducted through estrogen receptor alpha and beta, however ER-alpha (ERα) is thought to play a dominant role in breast carcinogenesis [2] . Upon ligand binding ERα is phosphorylated on several sites resulting in activation of estrogen-regulated genes involved in cell proliferation and survival [3] . Therefore, endocrine therapies such as Tamoxifen (Tam) that acts as a competitive ligand inhibitor of ERα and Fulvestrant (ICI-182, 780, ICI) which leads to ubiquitination and degradation of ERα protein [4] [5] [6] , are effective measures aimed at targeting ERα, thus limiting the proliferation and survival of ERα + breast cancer cells. These agents are very effective first and second-line endocrine therapies for all stages of ERα + breast tumours, however, a small number of these tumours show de novo resistance or after prolonged treatment acquired resistance to both agents can occur in about a third of initially responsive tumours. The development of endocrine therapy resistance (ETR) leads to cancer progression to metastatic disease therefore decreasing overall patient survival which poses a major clinical challenge [7, 8] . Mechanisms of acquired ETR have frequently been studied in the ER+ human breast cancer cell lines, MCF7 and T-47D. By placing MCF7 cells in ovariectomized immune-deficient mice, a new estrogen-independent cell line was obtained [9] . Additional cell lines that show resistance to Tam (LCC2) or ICI (LCC9) were generated after long-term exposure in vivo to these drugs. Studies using the LCC cell system have revealed that these ETR cells show high expression of ERα and are estrogen independent. Several mutations in the ERα gene have been identified that confer ligandindependent activity of ERα [10, 11] . Interestingly, decreasing ERα expression in the LCC9 cells results in cell death [12] however, mechanisms that can contribute to maintaining ERα expression in these ETR cells remains unknown.
We recently showed that the estrogen-induced proliferation of normal human ER+ breast epithelial cells requires expression of the H19 gene which is an estrogen-regulated breast oncogene [13] . Loss of H19 expression leads to decreased breast cancer cell proliferation and decreased tumour volume in mice [14, 15] . H19 is a long non-coding RNA that has been shown to regulate estrogen-induced proliferation of ERα + breast cancer cells and we recently showed that H19 also regulates the proliferation of ERα + normal human breast epithelial cells [13] . H19 RNA consists of the micro RNA675 (miR675) in its first exon which regulates cell proliferation by suppressing retinoblastoma (RB) gene expression [16] . As well, the exons 2-5 fragment of H19 limits the bioavailability of Let-7 microRNA, leading to increased cell proliferation [17, 18] . Based on the important role that H19 plays in regulating proliferation of normal and malignant ERα + breast cells, we hypothesize that H19 plays an equally important role in maintaining the ETR in therapy refractory tumours.
In this report, we demonstrate that decreasing H19 expression either by lentiviral transduction or by using pharmacological inhibitors that block Notch and c-MET receptor signaling, sensitizes the ETR cells to Tam and ICI in an H19-dependent manner. We further show that H19 modulates ERα expression in the ETR cells and might protect these cells against ICI-mediated cell death. The delivery of interfering RNA fragments to treat breast cancer patients has been challenging in the clinic. Therefore, based on our data, pharmacological inhibitors that block Notch and c-MET receptor signaling in combination with endocrine therapies might prove to be effective treatment options for patients with recurrent ERα + breast cancer.
Materials and Methods

Breast cancer cells
The Tamoxifen (Tam)-resistant LCC2 and the Fulvestrant and Tam (ICI 182, 780, ICI, Tam) crossresistant LCC9 cells were obtained from Dr. Robert Clarke (Georgetown University, Washington, DC) at low passage and were routinely maintained in phenol-red free (PRF) Improved Minimum Essential Medium (IMEM) (Thermo Fisher Scientific, Waltham, USA) supplemented with 5% charcoal-stripped serum (CSS, v/v) 2× charcoal/dextran-treated fetal bovine serum, FBS, (estrogen-depleted growth media) and 100 nM 4-hydroxytamoxifen (4-OHTam) or 100 nM ICI as described before [9] . The genetic relationship of the cell lines with the parental MCF-7 cell line was confirmed previously by DNA fingerprinting. ERα + MCF7 cells (originally obtained from Dr. McGuire (San Antonio, Texas [19] ) and T-47D cells (originally obtained from Dr. Dean Edwards (Baylor College of Medicine, Houston) [20] have been maintained in the current laboratory for > 20 years. These cells were authenticated on October, 2016 using STR analyses (Genetica Cell Line Testing, Labcorp, Burlington, NC, USA). All experiments were carried out on cells between passages 5-20. MCF7 were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% FBS and T-47D cells were maintained in Roswell Park Memorial Institute (RPMI)-1640 media (Sigma) supplemented with bovine Insulin (Sigma) and 10% FBS.
For some experiments, breast cancer cells were cultured to 60% confluency and treated with ICI (at the indicated doses), or 4-OHTam (100 nM) or a pan Notch signaling inhibitor RO4929097 (RO, at the indicated doses) or the c-MET receptor selective inhibitor Tivantinib (ARQ 197, TIV, at the indicated doses). Both inhibitors were from Selleckchem (Houston, TX, USA). To treat cells with a combination of these signaling inhibitors, LCC2, LCC9 or T-47D
ICI-Res or T-47D Tam-Res were grown to 60% confluency and treated with a combination of RO and TIV or RO or TIV and ICI or Tam or vehicle control for 1 or 3 days.
Gain and loss of H19 function in breast cancer cells
The full length H19 cDNA was purchased from Dharmacon (Colorado, USA) and was sequence verified. H19 cDNA was sub-cloned into pHIV-dTomato lentiviral vector (Addgene, Cambridge, MA, USA) [pHIV-dTomato was a gift from Bryan Welm to Addgene (Addgene plasmid # 21374)] and used to produce lentivirus which was then used to infect sub-confluent cultures of LCC9 (LCC9 dTOM H19FL) and LCC2 (LCC2 dTOM H19FL). Some cells were infected with empty dTomato (dTOM) expressing virus as controls. The transduced dTOM + breast cancer cells were sorted by a flow cytometer and further expanded for future experiments. To knockdown H19 expression in the resistant breast cancer cells, a pool of 3 different pGIPZpuro-GFP plasmids containing short hairpin (sh) RNA targeting the H19 RNA or a pGIPZ-puro-GFP vector (Thermo Fisher Scientific, Waltham, USA) expressing a scrambled sh-RNA fragment were used to generate lentivirus and then used to infect LCC2 and LCC9 cells. All cells were infected using a previously described protocol [13, 21] . Briefly, 5.5x10 5 cells were plated in 60 mm culture plates in PRF-IMEM supplemented with 5% CSS-FBS for 24hrs and then infected with 5-7x10 6 lentiviral particles for 6 hrs. After 4 days, the transduced GFP + breast cancer cells were sorted by a flow cytometer and expanded for future experiments. The successful knockdown or overexpression of H19 gene in the transduced cells were assessed using qPCR. NOTCH4-ICD (a constitutively active form of NOTCH4) cDNA carrying plasmid (MIY-NOTCH4-ICD) construct was a kind gift from Dr. Aly Karsan (Genomic Sciences Centre, B.C. Cancer Agency, Vancouver, Canada). The cDNA was cloned into lenti-viral vector KA391, sequence verified and used to produce lentivirus to infect the LCC9 cells as described. Empty KA391 vector was used as control. The transduced (GFP + ) LCC9 cells were isolated using flow cytometry. All cells were transduced with separate lentivirus to produce 3 independent biological replicates. 
Intracellular Flow cytometry
The transduced shH19-LCC2 and shH19-LCC9 or scramble-LCC2/-LCC9 cells were grown in 5% CSS-PRF medium for 48 hrs and treated with RO (250 mM), TIV (50 nM), ICI (100 nM), 4-OHTam (100 nM), or combinations of these inhibitors for an additional 24 hrs. Subsequently, single cell suspensions were fixed and permeabilized using BD Perm and Fix Kit (BD Biosciences, San Jose, CA, USA) as described before [13] . Fixed cells were then stained with anti ERα antibody (6F11, Abcam), and ERα expression was detected using an anti-mouse phycoerythrin (PE, Biolegend, San Diego, CA, USA) secondary antibody via flow cytometry. FlowJo software (Ashland, Oregon, USA) was used to obtain the Median Fluorescence Intensity (MFI) for all treatment groups and also for those treatment groups that specifically contained GFP+ cells.
Breast cancer cell-fibroblast co-cultures
The LCC2 and LCC9 cells (5 x10 4 ) were either cultured alone or placed in co-culture with tumourassociated fibroblasts (TAFs, 5 x10 4 ) using 12-well culture plates. TAFs were obtained from primary ERα + human breast tumours as described before [22] . Primary human breast tumours were obtained from informed consented patients in accordance with the University of Manitoba Research Ethics Board (REB# HS14919). TAFs were assessed to lack EpCAM (StemCell Technologies, Canada), CD45 (Biolegend, San Diego, USA), and CD31 (eBioscience, ThermoFisher Scientific, USA) expression but had strong α-smooth muscle actin and fibroblast specific protein 1 expression. Therefore, EpCAM expression was used to determine breast cancer cell numbers in the co-cultures. After 48 hrs, cells were treated with RO (250 mM), TIV (50 nM), and ICI (100 nM) or 4-OHTam (100 nM) or vehicle control for 24 hrs. Subsequently singlecell suspensions were stained with an anti EpCAM antibody and the number of viable (propidium iodide negative, PI -) EpCAM + cells was determined by flow cytometry.
Cell viability assay
Cancer cell viability was measured using the colorimetric water-soluble tetrazolium salt cell counting kit-8 (WST-8) assay (Dojindo Molecular Technologies, Rockville, MD, USA) as per manufacturer's protocol. Briefly, cells (1x10 4 ) were seeded in each well of a 96-well plate for 24 hrs and then growth medium was supplemented with different concentrations of ICI, 4-OHTam, RO, TIV or their combinations or vehicle control. Subsequently, cells were treated with the WST-8 reagent and after solubilisation of the purple formazan crystals, absorbance was measured at 450 nm (background wavelength, 650 nm) using a plate reader (Synergy H1 Hybrid Reader, BioTek, Vermont, USA).
Organoid Cultures LCC2 and LCC9 cells (5 x10 4 ) were plated into each well of 96-well plates containing 50 mL of polymerized, growth factor-reduced and PRF matrigel (BD Biosciences, San Jose, CA, USA). After 48 hr, the organoid-like structures were either treated with ethanol (vehicle control) or RO (250 mM), TIV (50 nM), and ICI (100 nM) or Tam (100 nM). After 7 days, cell viability was determined by WST-8 assay as described.
Statistical analysis
For all experiments, data were generated from at least three independent replicates and were expressed as average ± standard deviation (SD). Two-tailed Student's t-tests were used to determine statistical significance and for multi-pairwise comparisons ANOVA was used. All tests were done using GraphPad Prism 7 program (La Jolla, CA, USA).
Results
H19 regulates resistance to ICI and Tam in ETR cells
To assess if H19 expression is important to the development of endocrine therapy resistance, therapy sensitive MCF7 cells were cultured in estrogen-deprived growth conditions and exposed to ICI for up to 12 days and H19 expression was quantified (Fig. 1A) . Exposure to ICI initially resulted in decreased H19 expression after 24 hrs. Subsequently, H19 expression was significantly increased in the MCF7 cells after 3 days of ICI exposure and its high expression was sustained for up to 12 days, suggesting that H19 expression Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry might be associated with the development of endocrine therapy resistance. To test this hypothesis, H19 expression was examined in the Tam and ICI cross-resistant LCC9 and the Tam-resistant LCC2 cells. Interestingly, we observed a significant increase (2.05±0.31 fold) in H19 expression in LCC9 cells treated with ICI after 6 days compared to the untreated control cells (Fig. 1B) . In the case of LCC2 cells, treatment with Tam was required to maintain high expression of H19 (2.24±0.8 fold) (Fig. 1B) . Next, we examined if increased H19 expression was required for the Tam-and ICI-resistant phenotype in these cells. For this purpose, we measured cell viability in LCC9 and LCC2 cells transduced with lentivirus expressing a short . H19 expression was determined using qPCR after 1 and 6 days. In both cases, H19 expression was normalized to the GAPDH transcript levels and average transcript expression and standard deviation (SD) from 3 independent experiments are shown as bar graphs. H19 RNA levels were decreased in the LCC9 (C) and LCC2 (D) cells with shRNA using the lentiviral transduction (shH19LCC9, shH19LCC2). Scrambled shRNA expressing cells were used as controls (Sc-LCC9 and Sc-LCC2). Impact of ICI and Tam on viability of the transduced cells was measured relative to ethanol-treated cells (set to 100%). Average cell viability from at least 3 independent experiments and SD are shown in the graphs. *P<0.05, **P<0.005, ***P<0.0005, ****P<0.0005. (Fig. 1C-D) . However, when shH19-LCC9 or -LCC2 cells were treated with ICI or Tam for just one day, we observed a significant decrease in cell viability. After 3 days of treatment with ICI, only 4.15±3% of shH19-LCC9 cells was viable. Compared to the shH19-LCC9, the LCC2 cells showed less sensitivity to Tam with decreased H19 levels. However, after 3 days of Tam treatment, shH19-LCC2 cell viability was reduced to 13.12±0.6% (Fig. 1D ). These data indicate that H19 plays a role in maintaining the ETR phenotype and decreasing its expression overcomes resistance to ICI and Tam. To determine if H19 expression level is correlated with maintaining the ETR phenotype, the shH19-LCC9 cells with higher H19 expression (LCC9
H19high
) compared to the cells with lower H19 expression (LCC9 H19low ) were separated based on their GFP expression (Fig. S1B) . Interestingly, the ICI effects on decreasing cell viability were only observed when H19 levels were decreased by more than 70% i.e. in (>70%, LCC9
H19low ) compared to ineffective H19 knockdown (30%, LCC9 H19high ) (Fig. S1C) .
MET receptor signaling regulate H19 expression in ETR breast cancer cells
Since decreasing H19 expression in LCC9 and LCC2 cells helped overcome their resistance to ICI and Tam, we considered signaling pathways that might regulate H19 expression in these ETR cells and whether blocking such signaling pathways would overcome their resistance to endocrine therapies. Previous reports have indicated that HGF-c-MET signaling regulates H19 expression [23, 24] . Having established that the LCC9 and LCC2 cells express c-MET receptor (Fig. S2A) , we determined if c-MET receptor signaling regulated H19 expression in these ETR cells. Treatment with 50nM of a c-MET inhibitor, Tivantinib (TIV) was sufficient to reduce H19 expression by 2.61±0.74 fold (Fig. S2B) , with only a marginal effect on LCC9 and LCC2 cell viability after 3 days (81.43±1.95% and 86.47±1.22% respectively, Fig. 2A-B) . As well, in combination with ICI or Tam, TIV treatment only marginally affected LCC9 and LCC2 cell viability (down to 74.97±4% and 77.51±3.49% accordingly) ( Fig. 2A-B) . This finding was consistent with our observation that greater than 70% decrease in H19 expression is required to overcome resistance to ICI. These data suggest that other signaling pathways are also involved in regulating H19 expression in these ETR breast cancer cells. 
NOTCH4 and c-MET signaling together contribute to H19-dependent resistance to endocrine therapies
Previous reports suggested that Notch signaling, in particular Notch Receptor 4, NOTCH4, contributes to the ETR phenotype through enhanced epithelial to mesenchymal transition as well as regulating cancer stem cell activity [25, 26] . Interestingly, we observed that NOTCH4 transcript levels were significantly increased in ICI-treated LCC9 cells after 6 days (Fig. 3A) . Furthermore, forced expression of a constitutively active form of NOTCH4, significantly increased H19 expression in these cells (Fig. 3B) . Next, we determined that 250 mM of RO4929097 (RO), a pan Notch signaling inhibitor was sufficient to significantly decrease H19 and HES1 (a known NOTCH target) transcript levels (2.66±0.56 and 2.71±1.44 (Fig. S3A) . Interestingly however, RO treatment of the ICI/Tam-sensitive MCF7 cells had no effect on H19 expression while HES1 transcript levels were decreased (Fig. S3B) . The most significant decrease in H19 expression was observed when LCC9 and LCC2 cells were treated with a combination of RO, TIV and ICI or Tam (Fig.  3C-D) where H19 expression was decreased by 83.14±5.33% and 79.03±3.49% respectively. RO as a single agent was more effective than TIV or TIV+ICI in decreasing LCC9 and LCC2 cell viability after 3 days (32.02±01.99% and 27.47±1.28% respectively, Fig. 3E-F Tam-Res ) cells, indicating that our observations are not limited to the LCC9 and LCC2 cells (Fig. S3C) . Of note, even though TIV and RO are equally effective in decreasing H19 expression (<70%) as single agents in the LCC9 cells (Fig. 3C ), RO has a larger effect on decreasing cell viability compared to TIV (Fig. 3E-F) .
Our data so far indicate that sensitization of LCC9 and LCC2 cells to ICI and Tam when treated with Notch and c-MET receptor inhibitors might require decreased H19 expression. To test this hypothesis, LCC9 and LCC2 cells were transduced with lenti-virus to express full-length H19 (Fig. 4A ) and the transduced cells were treated with a combination of RO, TIV and ICI or Tam (Fig. 4B-C) . Interestingly, the H19 overexpressing ETR cells remained resistant to ICI and Tam when treated with combination of RO and TIV. However, RO and TIV treatment decreased cell viability in H19 overexpressing LCC9 & LCC2 cells by 17.65±5.61% and 16.83±1.56% (Fig. 4B-C) , suggesting that Notch and MET signaling contributes to ETR cell viability via H19-dependent and -independent mechanisms. However, the H19-dependent cell survival mechanisms play a more significant role than the H19-independent mechanisms. These observations together indicate that blocking Notch and c-Met receptor signaling together overcome resistance to ICI and Tam in ETR breast cancer cells in an H19-dependent manner.
H19 regulates ERα expression in ETR breast cancer cells
So far, our data indicate that significantly reduced H19 expression (>70%) sensitizes LCC9 and LCC2 cells to ICI and Tam, suggesting that ligand-independent ERα signaling is important to the survival of these ETR cells. We therefore examined ERα expression in LCC9 cells showing effective H19 knockdown (>70%, LCC9 H19low ) or ineffective H19 knockdown (30%, LCC9
H19high
) and found that ERα protein and transcript levels were both significantly decreased in the LCC9
H19low cells but not in the LCC9 H19high compared to control cells (Fig. 5A-B  and Fig. S4B ). Addition of ICI for 24 hours further decreased ERα protein expression in the LCC9 H19low cells (Fig. 5A) , suggesting that H19 expression protects ERα from ICI-mediated protein degradation. Similar results were found using the LCC2 H19low cells (Fig. S4A) . Although statistically significant, the decreased ERα protein levels in the LCC2
H19low cells was small and not effected further by Tam as is consistent with Tam's mechanisms of action as a competitive inhibitor and not a down-regulator of ERα. However importantly, treating LCC9 and LCC2 cells with a combination of RO, TIV, and ICI or Tam significantly decreased ERα expression in these ETR cells (Fig. 5C-D) . Interestingly, we found that knocking down ERα in the LCC9 cells also decreased H19 expression (Fig. S4C) providing further support to the notion that ERα signaling is regulated primarily in a ligand-independent manner in the LCC9 cells.
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
Blocking Notch and c-MET signaling sensitizes ETR cells to endocrine therapy in 3D organoid cultures
To examine if the combination of RO and TIV could overcome ICI and Tam resistance in a more in vivo-like environment, LCC9 and LCC2 cells were placed in 3 dimensional (3D) organoid cultures. Live EpCAM + cells were quantified to determine breast cancer cell number in these co-cultures. We observed that in organoid cultures treated with a combination of RO, TIV and ICI or Tam, cell viability was significantly decreased (to 31.06±5.87% and 29.79±7.96% of untreated controls, respectively, Fig. 6A-C) . Recent evidence supports a Cellular Physiology and Biochemistry strong role for tumour microenvironment, in particular the tumour-associated fibroblasts (TAFs), as a major modulator of therapy resistance in breast tumours [27, 28] . We therefore examined if blocking Notch and c-MET signaling could sensitize ETR cells to endocrine therapies in the presence of TAFs. For this purpose, LCC9 and LCC2 cells were placed in 2D co-culture with and without TAFs and treated with RO, TIV, ICI or Tam for 24 hr. Interestingly, breast cancer cell numbers were significantly decreased in co-cultures treated with RO, TIV, ICI or Tam even more so compared to cancer cell alone cultures (Fig. 6D-E) . Lastly, we examined the clinical relevance of c-MET, NOTCH4, and H19 expression to overall survival of patients with ER+ breast tumours using the TCGA and METABRIC data sets. The transcript expression level for each gene and the combined risk score were binarized into high risk and low risk groups as described in the Supplementary Information. The correlation and differences in overall survival between these risk groups were assessed by Kaplan-Meier analysis. The combined (H19+NOTCH4+MET) high risk score was significantly associated with poorer overall survival in both cohorts (TCGA data set: Hazard Ratio (HR) = 1.90 (1.11-3.24), P=0.019; METABRIC data set: HR=3.51 (1.47-8.34), P=0.0045). These data indicate that high expression of H19, NOTCH4 and MET is associated with poor prognosis in ER+ breast cancers (Fig. S5A-B ).
Discussion
Although ER+ breast tumours respond well to endocrine therapies such as ICI and Tam, over 30% of these tumours develop resistance or exhibit de novo resistance to such therapies [8] . These recurrent tumours retain ERα expression and yet are refractory to the effects of ICI and Tam. In this study, we report that H19 expression is essential to endocrine therapy resistance in breast cancer cells. We found that Notch and c-MET signaling together regulate H19 expression in the ETR cell line models used in this study. Moreover, pharmacological inhibitors of Notch and c-MET receptor signaling in combination yield significant (>70%) decreased H19 expression and overcome resistance to ICI and Tam in these cells in an H19-dependent manner. As a non-protein coding gene, H19 poses a significant challenge as a therapeutic target. Therefore, our finding that pharmacological inhibitors of Notch and c-MET receptor signaling overcome resistance in ETR cells through decreased H19-ERα expression could have significant clinical implications. Moreover, we found that H19 regulates ERα expression and protects ERα from ICI and Tam antagonist action. It is interesting that while ERα levels were reduced in the ETR cells with decreased H19 expression, no effect on cell viability was detected. However, in the presence of ICI, further reduction in ERα expression occurred and this was associated with a significant decrease in cell viability in the LCC9 suggesting that ERα protein in the shH19-ETR cells had become susceptible to ICI-induced protein degradation. A previous report by Cook et al. [12] also indicated that decreased ERα renders LCC9 cells susceptible to ICI where they observed a 50% decrease in relative cell density after 3 days of ICI treatment. Based on our finding that H19 regulation of ERα is reciprocated by ERα, we posit that the sensitization of ERα-knocked down LCC9 cells to ICI reported by Cook et. al., [12] was due to decreased H19 levels. However, here we report >90% cell loss in shH19-LCC9 cells exposed to ICI for 3 days. This difference in results could be explained in two ways. Cook et. al., used an RNAi strategy, which as a transient methodology to knockdown ERα levels will be effective acutely, but after 3 days the nontransfected cells would have expanded in these cultures. We used lentiviral transduction followed by purification of the cells that were expressing the shH19 construct, using flow cytometry. Also, Cook et. al., measured cell growth using crystal violet labeling after 3 days of exposure to ICI. Crystal violet stains all live and dead cells. In our study, we used cell viability assays to measure the impact of ICI exposure to decreased H19 expression in the LCC9 and LCC2 cells. These data suggest that the ICI-resistant LCC9 cells are still reliant on ERα-regulated cell survival signals which are presumably activated in a ligand-independent manner [9] . The ligand-independent activation of ERα due to somatic mutations [29, 30] or as yet unidentified mechanisms have made targeting ERα in the endocrine therapy resistant breast cancer cells very challenging. Therefore, our finding that H19 regulates ERα gene expression in ETR cells has great clinical significance. While H19 expression has been associated with tumour progression and therapy resistance in many cancers, to the best of our knowledge a role for H19 in endocrine therapy resistance has not been described before. H19 RNA consists of a micro-RNA (miR675) shown to decrease retinoblastoma gene expression [15, 31] . The exons 2-5 H19 RNA fragment has been reported to limit bioavailability of different non-coding RNAs such as Let-7A and miR-484 [17, 32] . It is therefore inviting to hypothesize that reduced H19 expression increases availability of miRs that subsequently decrease ERα transcript levels. A recent report suggested that H19 inhibits RNA Pol II-mediated transcription by disrupting the hnRNP U-active complex [33] , indicating that H19 could influence the transcription of its target genes by effects on these nuclear proteins. Therefore, it is possible that H19 might indirectly regulate ERα transcription and subsequently protein levels in the ETR cells. ICI acts as an anti-estrogen by binding to ER, resulting in an enhanced degradation via ubiquitination/proteosomal mechanism, while Tam acts as a competitive inhibitor of ER and when bound to ER causes a conformational change that inhibits the recruitment of coactivators and enhances recruitment of corepressor complexes. Here we report that in ICI and Tam-resistant breast cancer cells, decreased H19 levels result in decreased ER levels, and by some as yet unknown mechanism the remaining ER proteins have become again susceptible to both ICI-induced degradation and Tam inhibitory action, leading to decreased viability of these previously therapy-resistant cells.
Conclusion
Taken together, our findings indicate that H19 plays a central role in maintaining endocrine therapy resistance by modulating ERα expression in these cells. Moreover, decreasing H19 levels using pharmacological inhibitors, that inhibit pathways regulating H19 expression in the ETR cells, helps overcome Tamoxifen and Fulvestrant-resistance.
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